Evolocumab vs Ezetimibe: Study Links Injectable Drug

What did the evolocumab versus ezetimibe study find?

Amgen announced the findings on November 5, describing an analysis of U.S. healthcare records involving adults with atherosclerotic cardiovascular disease and previous statin use. Researchers compared people starting evolocumab, marketed as Repatha, with those starting ezetimibe. According to the manufacturer, the findings were published in the American Journal of Preventive Cardiology. [Amgen study announcement](https://www.amgen.com/newsroom/press-releases/2026/11/repatha-lowers-risk-of-heart-attacks-by-20-compared-with-ezetimibe-in-a-large-realworld-study).

The headline percentage describes a relative difference in heart attack hazard, not a 20-percentage-point reduction in an individual's chance of having one. Absolute benefit depends on baseline cardiovascular risk and the period being considered. The population already had cardiovascular disease, so applying this finding to otherwise healthy people with mildly elevated cholesterol would go beyond the study's scope.

Does this prove evolocumab is better for every patient?

The researchers used a target trial framework, organizing routinely collected data to approximate a clinical trial, and statistical weighting to balance measured characteristics. However, treatment was not randomly assigned. Unmeasured differences between patients can still influence outcomes, even in a very large analysis. The manufacturer's announcement should therefore be read as evidence of an association rather than definitive proof of comparative superiority. [Study design and methods](https://www.amgen.com/newsroom/press-releases/2026/11/repatha-lowers-risk-of-heart-attacks-by-20-compared-with-ezetimibe-in-a-large-realworld-study).

Randomized trials already support cardiovascular benefits from both medicines in appropriate settings. FOURIER showed that adding evolocumab to statin therapy reduced a composite of cardiovascular events compared with placebo. IMPROVE-IT showed that adding ezetimibe to simvastatin improved cardiovascular outcomes after an acute coronary syndrome. These trials establish that both approaches can help; they did not directly compare evolocumab against ezetimibe. [FOURIER trial](https://www.nejm.org/doi/full/10.1056/NEJMoa1615664), [IMPROVE-IT trial](https://www.nejm.org/doi/full/10.1056/NEJMoa1410489).

How should patients discuss additional cholesterol treatment?

The medicines lower LDL cholesterol through different pathways. Evolocumab is an injected antibody that blocks PCSK9, helping the liver retain receptors that remove LDL from the blood. Ezetimibe reduces cholesterol absorption in the intestine. Evolocumab can cause injection-site reactions, and serious allergic reactions are a recognized risk. These practical and safety considerations belong alongside evidence about cardiovascular benefit. [FDA Repatha prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125522s049lbl.pdf), [Ezetimibe clinical evidence](https://www.nejm.org/doi/full/10.1056/NEJMoa1410489).

The ACC/AHA dyslipidemia guideline retains statins as the foundation of treatment for people with established cardiovascular disease and includes additional medicines when needed. Selection depends partly on how much further LDL must fall and what treatment the patient can sustain. A useful appointment should establish the person's LDL goal, review their current medicines and side effects, and consider affordability and willingness to use injections before changing treatment. [ACC/AHA dyslipidemia guideline](https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016).